Barclays PLC Has $157,000 Position in Harvard Bioscience, Inc. (NASDAQ:HBIO)

Barclays PLC increased its holdings in shares of Harvard Bioscience, Inc. (NASDAQ:HBIO) by 304.4% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 58,655 shares of the medical instruments supplier’s stock after buying an additional 44,150 shares during the period. Barclays PLC owned about 0.13% of Harvard Bioscience worth $157,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in the business. Geode Capital Management LLC lifted its position in shares of Harvard Bioscience by 2.2% in the 3rd quarter. Geode Capital Management LLC now owns 912,599 shares of the medical instruments supplier’s stock worth $2,455,000 after purchasing an additional 19,972 shares during the period. State Street Corp increased its stake in shares of Harvard Bioscience by 1.1% in the 3rd quarter. State Street Corp now owns 717,387 shares of the medical instruments supplier’s stock valued at $1,930,000 after acquiring an additional 7,763 shares in the last quarter. Harvey Partners LLC increased its stake in shares of Harvard Bioscience by 6.2% in the 3rd quarter. Harvey Partners LLC now owns 2,715,000 shares of the medical instruments supplier’s stock valued at $7,303,000 after acquiring an additional 157,500 shares in the last quarter. Corsair Capital Management L.P. bought a new stake in shares of Harvard Bioscience in the 3rd quarter valued at $63,000. Finally, Advantage Alpha Capital Partners LP bought a new stake in shares of Harvard Bioscience in the 3rd quarter valued at $64,000. 80.87% of the stock is currently owned by institutional investors and hedge funds.

Harvard Bioscience Stock Performance

NASDAQ:HBIO opened at $1.95 on Thursday. The firm has a market capitalization of $85.06 million, a P/E ratio of -5.91 and a beta of 1.27. The company has a fifty day moving average of $2.13 and a 200-day moving average of $2.55. The company has a quick ratio of 0.91, a current ratio of 2.06 and a debt-to-equity ratio of 0.52. Harvard Bioscience, Inc. has a twelve month low of $1.81 and a twelve month high of $4.93.

Harvard Bioscience Company Profile

Harvard Bioscience, Inc develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings.